Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-10-20
1999-09-28
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514183, 514221, 540473, 540567, C07D48704, C07D47104, C07D 3155, C07D 31495
Patent
active
059589205
ABSTRACT:
Certain aralkyl diazabicycloalkyl compounds are disclosed for treatment of CNS disorders, such as cerebral ischemia, psychosis and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein m is three or four; wherein z is selected from the group consisting of ##STR2## wherein when Z is ##STR3## n and p are integers of from one to four, with a sum of four or five, and when Z is ##STR4## n and p are integers of from one to three, with a sum of three or four; wherein A is selected from the group consisting of aryl, heteroaryl, aryloxy, heteroaryloxy, aralkoxy, heteroaralkoxy, arylamino, heteroarylamino, aralkylamino, heteroaralkylamino, arylthio, heteroarylthio, aralkylthio, and heteroaralkylthio; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from the group consisting of hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, halo, haloalkyl, hydroxyalkyl, cyano, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, alkanoyl, alkenyl and alkynyl; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4204003 (1980-05-01), Szmuszkovicz
patent: 4463013 (1984-07-01), Collins et al.
patent: 4801604 (1989-01-01), Von Voightlander
Aram et al., J. Pharmacol. Exp. Ther., 248, 320-328 (1989) (Abstract).
Bailey et al. Eur. J. Pharmacol., 240, 243 (1993) (Abstract).
Bellville, Clin. Pharm. Ther., 9, 142 (1968).
Canoll et al., J. Neurosci. Res., 24, 311-328 (1989) (Abstract).
Carter et al., J. Pharm Exp. Ther., 247(3), pp. 1222-1232 (1988).
Chouinard, Psychopharmacology, 84, 282 (1984).
Clissold, J. Pharm. Exp. Therapeutics, 265, 876 (1993).
Contreras et al., Brain Res., 546, 79-82 (1991).
Cook et al., J. Pharmacol. Exp. Ther., 263, 1159-1166 (1992) (Abstract).
De Costa et al., J. Med. Chem., 32(8), 1996-1002 (1989).
De Costa et al., J. Med. Chem., 35(1), 38-47 (1992).
De Costa, Brain Res., 671, 45 (1995).
De Costa, J. Med. Chem., 35, 4334 (1992).
De Costa, J. Med. Chem., 36, 2311 (1993).
De Costa et al., Brain Res., 671, 45-53 (1995) (Abstract).
DeHaven-Hudkins et al., Life Sci., 56, 1571-1576 (1995).
Forrest, Clin. Pharm. Ther., 10, 468 (1969).
Gewirtz, Neuropsychopharmacology, 10, 37-40 (1994).
Giardina, Biosytemi Come Targets Farmacologici Recettori Peptidergici, 21-63 (1992).
Gilman et al., The Pharmacological Basis of Therapeutics, 7.sup.th Edition, 404 (1985).
Goldberg, J. Pharm. Exp. Ther., 243, 784 (1987).
Gonzalez et al., J. Pharm Exp. Therapeutics, 271, 212 (1994).
Gonzalez-Alvean, Brain Res., 673, 61 (1995).
Hadkins, Life Sci., 49 p. 1229 (1992).
Hudkins et al., Life Sci., 49(17), 1229-1235 (1991).
Itzhak et al., FASEB J., 3, 1868-1872 (1989).
Izhak et al., "Sigma Receptors" Acedemic Press, 191-204 (1994).
Kirk et al., J. Pharmacol. Exp. Ther., 271, 1080-1085 (1994) (Abstract).
Klein et al., J. Pharmacol. Exp. Ther., 260, 990-999 (1992) (Abstract).
Klein et al., Eur. J. Pharmacol., 254, 239-248 (1994).
Lasage et al., Synapse, 20, 156-64 (1995) (Abstract).
Lason et al., Brain Res., 482, 333-339 (1989).
Lobner, Neurosci Letters, 117, 169 (1990).
Long et al., Soc. Neurosci. Abs., 16, 1122, abstract 461.4 (1990).
Loscher et al., Eur. J. Pharmacol., 238, 191-200 (1993).
Lysko et al., Stroke, 23, 1319-1323 (1992) (Abstract).
Lysko et al., Stroke, 23, 414-419 (1992) (Abstract).
Parsons et al., Neuropharm., 25(2), 217-220 (1986).
Pontecorvo, Brain Res. Bulletin, 26, 461-465 (1991).
Radesca et al., J. Med. Chem., 34(10), 3058-3065 (1991).
Ragowski, Drugs, 44, 279 (1992).
Ragowski, J. Pharm. Exp. Therepeutics, 259, 30 (1991).
Ragowski, TIPS, 14, 325 (1993).
Reddy et al., J. Med. Chem., 37, 260-267 (1994) Abstract only.
Rees, Biosystemi Come Targets Farmacologici Recettori Peptidergici, 65-101 (1992).
Ronsisvale, Biosystemi Come Targets Farmacologici Recettori Peptidergici, 102-103 (1992).
Roth et al., Eur. J. Pharmacol., 236, 327-331 (1993).
Rothman et al., Annals of Neurology, 19(2), 105-111 (1986).
Scopes et al., J. Med. Chem., 35, 490-501 (1992).
Simon, Science, 226, 850 (1984).
Takahashi et al., Stroke, 26, 1676-1682 (1995) (Abstract).
Tortella et al., Trends Pharmacol. Sci., 10, 501-507 (1990).
Tortella et al., Trends Pharmacol. Sci., 11, 146-147 (1990).
Walker, Clin. Neuropharmacology, 12, 322 (1989).
Weissman et al., Biol. Psych., 29, 41-54 (1991).
Weissman et al., Biol. Psychiatry, 29, 41-54 (1991) (Abstract).
Witkin et al., J. Pharmacol. Exp. Ther., 266, 473-482 (1993).
Bowen Wayne
de Costa Brian R.
Dominguez Celia
He Xiao-Shu
Rice Kenner C.
Berch Mark L.
The United States of America as represented by the Department of
LandOfFree
Aralkyl diazabicycloalkane derivatives for CNS disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aralkyl diazabicycloalkane derivatives for CNS disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aralkyl diazabicycloalkane derivatives for CNS disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703435